That didn’t take long- Welcome Back Ron Zwanziger

That didn’t take long- Welcome Back Ron Zwanziger

Just days after his non-compete agreement expired, Ron Zwanziger CEO of Alere (NYSE:ALR) is back in the diabetes business as Alere announced they have acquired Arriva Medical for $65 million. According to a press release issued back on Wednesday:

“Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has acquired Arriva Medical, a leading provider of diabetes testing supplies to individuals in their homes. To acquire Arriva, Alere paid approximately $65 million cash, subject to working capital and other closing adjustments, plus 806,452 restricted shares of Alere common stock. Based in Coral Springs, Florida, Arriva had revenues of approximately $21.5 million for the six months ended October 31, 2011.”

For anyone new to the wacky world of diabetes, Mr. Zwanziger has a long and distinguished history in the diabetes device world as he has built and sold, not one but two different glucose monitoring companies. The first was MediSense which he sold to Abbott (NYSE:ABT), the second Inverness Medical was sold to Johnson and Johnson (NYSE:JNJ). It was this second deal that came with his lengthy absence from the diabetes world as the last thing JNJ wanted was for him to compete against the company they just bought.

What makes Mr. Zwanziger return so exciting is his fondness for disruptive technology combined with his unique understanding of how the diabetes market works in the real world. Unlike so many others in this business who see technology as the end all be all and often forget that there is a real person with diabetes out there who must actually use this technology, Mr. Zwanziger isn’t one who believes that his company will sell more meters just because they come in pretty colors.

With this acquisition of Arriva, which by the way will be the first of what Diabetic Investor anticipates will be several diabetes related acquisition’s for Alere,  Mr. Zwanziger is laying the foundation to once again create havoc. Although he’s been away from the business for some time it would foolish not to take anything he does seriously and the big boys better be ready as we don’t suspect it will take him that long to get his diabetes strategy ramped up and moving forward.

Diabetic Investor welcomes his return as it will bring a much needed breathe of fresh air into what has become a rather dull business. If there is any executive who can handle the many issues facing the diabetes market and run a successful diabetes strategy Ron Zwanziger is that executive. Like Terry Gregg the CEO at Dexcom (NASDAQ:DXCM), Mr. Zwanziger is one of the few diabetes executive who gets it. Besides a wealth of experience these two men have proven time and time again they know how to run a successful diabetes company. Frankly it’s a shame that there are not more executives like these two men but there are only a few true diabetes superstars.

So fasten your seat belts as the diabetes market is about to begin what should one wild and fun ride. Welcome back Mr. Zwanziger, the latest guest to check back into Hotel California or as we like to call it the wacky world of diabetes.